← Eichor
Condition: Idiopathic Inflammatory Myositis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Idiopathic Inflammatory Myositis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammato
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06599411Descartes-08 in Autoantibody Myositis
Phase 2 · 2 location(s) · Cartesian Therapeutics · NCT07391605A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Optimizing Treatment on Idiopathic Inflammatory Myopathies
Phase N/A · 1 location(s) · University of Sao Paulo · NCT03092180Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis
Phase 2/Phase 3 · 2 location(s) · Restem, LLC. · NCT07160205To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiv
Phase 2 · 24 location(s) · Incyte Corporation · NCT05090891A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Phase 1 · 2 location(s) · Beijing GoBroad Hospital · NCT06980597Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1 · 77 location(s) · Chugai Pharmaceutical · NCT06371417Natural History of Inflammatory Muscle Diseases
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT05738824Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06828042Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University General Hospital · NCT07022197Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Phase N/A · 1 location(s) · University Hospital, Toulouse · NCT05251415Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06569472A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants Wit
Phase 1 · 37 location(s) · AstraZeneca · NCT06916806GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
EARLY_Phase 1 · 1 location(s) · Daishi Tian · NCT07086404Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Phase 2 · 1 location(s) · The Cleveland Clinic · NCT06857240A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Phase 1 · 19 location(s) · GlaxoSmithKline · NCT07371468Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Phase 2 · 8 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT07103746CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathie
Phase 3 · 146 location(s) · Pfizer · NCT05895786A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
Phase 1 · 1 location(s) · iCell Gene Therapeutics · NCT07715136Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
NA · 1 location(s) · Oslo University Hospital · NCT06732674A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06978647ILD-SARDs Registry and Biorepository
Phase N/A · 1 location(s) · McGill University Health Centre/Research Institute of the Mc · NCT05007340Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositi
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT00059748CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NA · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06379646
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.